Jan 15th 2013 - Edison Investment Research today published a report on ArQule entitled "CRC Study Misses, HCC Trial Starts". In summary, the report says:
The failure of tivantinib to show a statistically significant increase in PFS in a Phase II trial in second-line metastatic colorectal cancer (mCRC) makes further development in this disease setting a challenging prospect for ArQule and its partners. Meanwhile, the Phase III trial in second-line hepatocellular carcinoma (HCC) is now underway, with the first clinical sites now open for patient enrolment. Despite its recent clinical study misfortunes, ArQule remains on solid financial ground, with an estimated $130m of cash and cash equivalents at the end of 2012, sufficient to support operations into 2015, when final data of the Phase III HCC trial should become available.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »